Gilteritinib is a newer, selective, oral FLT3 inhibitor and was FDA-approved in 2018 for patients with relapsed/refractory AML harboring a FLT3 mutation as detected by an FDA-approved test [84]. Here, FLT3 is linked to acute myeloid leukemia.